Please assess the completion status of the following clinical trial:

Trial Title: Bronchodilator Effect of CHF1535 pMDI Versus Free Combination of Beclometasone Plus Formoterol pMDI in Asthmatic Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent obtained from the parents/legal representatives and/or the subject (if and when appropriate)~* Prepuberal male and female outpatients, aged ≥ 5 and \< 12 years (Tanner stage I and II)~* Clinical diagnosis of asthma according to Global Strategy for Asthma Management and Prevention (GINA) revised version 2009 at least six months prior to screening visit.~* Already treated with inhaled short acting Beta2-agonists as required and / or inhaled beclomethasone dipropionate up to 400 µg or equivalent.~* Forced Expiratory Volume during the first second (FEV1) ≥ 60% and ≤ 95% of predicted normal values at the screening visit.~* A documented positive response to the reversibility test at the screening visit, defined as Delta FEV1 ≥ 15% over baseline, 15 minutes after 400 μg salbutamol pressurised Meter Dose Inhaler (ATS/ERS taskforce 2005).~* A cooperative attitude and ability to use a pMDI and a spacer (Aerochamber Plus and Volumatic).~Exclusion Criteria:~* Endocrinological diseases or other chronic diseases.~* Known sensitivity to the components of study medication.~* Any concomitant disease requiring additional treatment with topic or systemic glucocorticosteroids.~* Allergy to one component of medications used.~* Intolerance or contra-indication to treatment with Beta2-agonists and/or inhaled corticosteroids.~* Having received an investigational drug within 2 months before the current study.~* Inability to comply to study procedures or to study treatment intake.~* Occurrence of acute asthma exacerbations or respiratory tract infections in the 4 weeks preceding the screening visit.~* Significant seasonal variation in asthma or asthma occurring only during episodic exposure to an allergen or a chemical sensitizer.~* History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency.~* History of near fatal asthma (e.g. brittle asthma, hospitalisation for asthma exacerbation in Intensive Care Unit).~* Diagnosis of restrictive lung disease.~* Significant medical history and/or treatments for cardiac, renal, neurological, hepatic, endocrine diseases, or any laboratory abnormality indicative of a significant underlying condition, that may interfere with patient's safety, compliance, or study evaluations, according to the investigator's opinion.~* QTc interval (Fridericia's formula) higher than 450 msec at screening visit

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: EXPERIMENTAL): CHF 1535 50/6 administered via a pMDI with spacer, 1 inhalation (dose: BDP 50 µg/FF 6 µg) + placebo HFA pMDI with spacer, 5 inhalations in the morning at the clinic
- Treatment B: (Type: EXPERIMENTAL): CHF 1535 50/6 administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg/FF 12 µg) + placebo HFA pMDI with spacer, 4 inhalations in the morning at the clinic
- Treatment C (Type: EXPERIMENTAL): CHF 1535 50/6 (dose: BDP 200 µg/FF 24 µg) administered via a pMDI with spacer, 4 inhalations (dose: BDP 200 µg/FF 24 µg) in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic
- Treatment D (Type: ACTIVE_COMPARATOR): formoterol 6 µg HFA administered via a pMDI with spacer, 2 inhalations (dose: FF 12 µg) + extrafine BDP 50 µg, administered via a pMDI with spacer, 2 inhalations (dose: BDP 100 µg), in the morning at the clinic + placebo HFA pMDI with spacer, 2 inhalations in the morning at the clinic
- Treatment E (Type: PLACEBO_COMPARATOR): placebo pMDI with spacer, 6 inhalations in the morning at the clinic

Based on this trial design, predict the completion outcome and termination type (if applicable).